Dec 16 (Reuters) - BASILEA PHARMACEUTICA AG:
* BASILEA PLANS PROGRESSION OF ONCOLOGY CANDIDATE LISAVANBULIN TO TARGETED, BIOMARKER-DRIVEN PHASE 2 STUDY
* BASILEA PHARMACEUTICA AG - CONFIRMED SIGNALS OF EFFICACY WITH PROFOUND RESPONSES IN TWO PATIENTS WITH GLIOBLASTOMA ACROSS TWO DIFFERENT CLINICAL STUDIES
* BASILEA PHARMACEUTICA AG - PLAN TO PROCEED WITH TARGETED, BIOMARKER-DRIVEN ORAL EXPANSION STUDY IN MID-2020 Source text for Eikon: Further company coverage: (Gdansk Newsroom)
Our Standards: The Thomson Reuters Trust Principles.